---
title: Anticoagulants & Fibrinolytics
markmap:
  colorFreezeLevel: 6
---

## Anticoagulants

- **Heparins**
  - **Unfractionated Heparin (UFH)**
    - Mechanism: Activates Antithrombin III (AT III) -> inhibits Factors IIa, Xa, IXa, XIa, XIIa
    - Monitoring: aPTT
    - Indications: DVT/PE treatment, ACS, Mechanical heart valves, bridge to Warfarin, Dialysis
    - Side effects: Bleeding, **Heparin Induced Thrombocytopenia (HIT)**, Osteoporosis (long-term)
    - Reversal: Protamine Sulfate
  - **Low Molecular Weight Heparins (LMWH)**
    - Drugs: Enoxaparin, Dalteparin
    - Mechanism: Preferentially inhibits Factor Xa via AT III
    - Monitoring: Anti-Xa assay (esp. in pregnancy, renal failure, extremes of weight)
    - Indications: DVT/PE treatment/prophylaxis, ACS, Cancer-associated thrombosis, Pregnancy
    - Side effects: Bleeding, less HIT risk than UFH, Injection site hematoma
    - Reversal: Protamine Sulfate (partial)
  - **Fondaparinux**
    - Mechanism: Selective Factor Xa inhibitor via AT III
    - Monitoring: Anti-Xa assay (not routine)
    - Indications: DVT/PE treatment/prophylaxis
    - Side effects: Bleeding, NO HIT risk (synthetic)
    - Reversal: No specific reversal agent (consider Activated Factor VIIa or PCC)

- **Vitamin K Antagonists**
  - **Warfarin**
    - Mechanism: Inhibits Vitamin K Epoxide Reductase (VKORC1) -> inhibits synthesis of Factors II, VII, IX, X, Protein C, Protein S
    - Monitoring: PT/INR (Target INR typically 2-3 for DVT/PE, AF; higher for mechanical valves)
    - Indications: AF, Mechanical heart valves, DVT/PE prophylaxis (long-term), Rheumatic mitral stenosis
    - Side effects: Bleeding (major concern), Skin necrosis (Protein C deficiency), Teratogenicity (**Contraindicated in Pregnancy - causes Warfarin embryopathy**)
    - Interactions: **Numerous drug & food interactions** (CYP enzymes, Vitamin K rich foods)
    - Reversal: **Vitamin K** (oral/IV), **Prothrombin Complex Concentrate (PCC)**, Fresh Frozen Plasma (FFP)

- **Direct Oral Anticoagulants (DOACs)**
  - **Direct Thrombin Inhibitors (Factor IIa)**
    - Drug: **Dabigatran**
    - Mechanism: Direct reversible competitive inhibitor of thrombin (free & clot-bound)
    - Monitoring: No routine monitoring needed (Diluted Thrombin Time or ECT can be used)
    - Indications: Non-valvular AF, DVT/PE treatment/prophylaxis
    - Side effects: Bleeding, Dyspepsia
    - Reversal: **Idarucizumab (Praxbind)**
  - **Direct Factor Xa Inhibitors**
    - Drugs: **Rivaroxaban**, **Apixaban**, Edoxaban
    - Mechanism: Direct reversible inhibitors of Factor Xa
    - Monitoring: No routine monitoring needed (Anti-Xa assay can be used)
    - Indications: Non-valvular AF, DVT/PE treatment/prophylaxis, Prophylaxis post ortho surgery
    - Side effects: Bleeding
    - Reversal: **Andexanet Alfa (AndexXa)** (for Rivaroxaban/Apixaban), Activated Charcoal (if recent ingestion), PCC

## Fibrinolytics (Thrombolytics)

- **Mechanism:** Convert Plasminogen to Plasmin -> degrades Fibrin clot
- **Drugs:**
  - **Streptokinase:** Bacterial product, antigenicity (can't reuse within ~6 months), hypotension
  - **Alteplase (rt-PA):** Recombinant human tPA, fibrin-specific
  - **Reteplase, Tenecteplase:** Modified rt-PA, longer half-life, bolus dosing
- **Indications (Specific Scenarios):**
  - **Acute Ischemic Stroke:** Within 4.5 hours of symptom onset (Alteplase)
  - **ST-Elevation Myocardial Infarction (STEMI):** If PCI not available within 90-120 mins
  - **Acute Massive Pulmonary Embolism (PE):** Hemodynamically unstable PE
  - Acute limb ischemia (selected cases)
- **Contraindications:**
  - **Absolute (Stroke):** Active internal bleeding, History of ICH, Intracranial neoplasm/AVM/aneurysm, Recent (3 months) stroke/head trauma/intracranial surgery, Severe uncontrolled hypertension (>185/110 mmHg), Active PUD, INR > 1.7 (if on Warfarin), Platelets < 100,000
  - **Relative:** Pregnancy, Recent major surgery (within 14 days), Recent GI/GU bleed (within 21 days), Traumatic CPR, Subacute bacterial endocarditis, Acute pericarditis
- **Side effects:**
  - **Bleeding:** Intracranial Hemorrhage (ICH - most feared), GI bleed, injection site bleeding
  - Angioedema (especially with ACE inhibitors and tPA)

## INICET Buzzwords

- **HIT**
- **Warfarin Embryopathy**
- **INR goal 2-3 vs 2.5-3.5**
- **Protamine Sulfate dose calculation**
- **PCC vs FFP for rapid reversal**
- **Non-valvular AF**
- **Cancer-associated thrombosis (LMWH)**
- **Peri-procedural bridge (UFH/LMWH)**
- **tPA window in stroke**
- **Contraindications to thrombolysis**
- **Idarucizumab/Andexanet Alfa**
- **Vitamin K dependent factors (2,7,9,10, C, S)**

